Eli Lilly and Company has concluded the acquisition of biopharmaceutical company Morphic Holding at $57 per share, a strategic move aimed at bolstering its inflammatory bowel disease (IBD) portfolio.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.06% and ...

Eli Lilly and Company announced the successful completion of its acquisition of Morphic Holding, Inc. Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) has finalized its purchase of biopharmaceutical firm Morphic Holding, Inc. (NASDAQ: NASDAQ:MORF), a move aimed at enhancing its portfolio of ...

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a biopharmaceutical company developing oral ...

Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) has finalized its purchase of biopharmaceutical firm Morphic Holding, Inc. (NASDAQ: NASDAQ:MORF), a move aimed at enhancing its portfolio of ...

INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a ...

2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a biopharmaceutical company ...